CORona (COVID-19) Follow Up Study: Epidemiology, Pathophysiology, Prediction, and Communication

NCT05240742 | Completed

• 1 other identifier: METC2021-2990
• Study Type: observational
• Target: 4,291
• Locations: 1 country
• Sites: 1

Brief Summary

The CORFU study, funded by ZonMW, is a prospective, multiple, cohort study with a maximum follow-up of 24 months after COVID-19. Dutch COVID-19 patients from 7 existing prospective cohorts, aiming and designed to conduct COVID-19 research, will be included in this study. The CORFU study has 5 aims, divided into 4 work packages (WPs):

1. 1.To describe the nature, severity, pattern and duration of long COVID complaints up to a maximum of two years after infection and its relationship with quality of life (WP1);
2. 2.To describe the rehabilitation and corresponding activities for the treatment and improvement of complaints and quality of life (WP1);
3. 3.To describe the pathophysiological processes that cause long COVID complaints, and the role of vulnerability/resilience factors (WP2);
4. 4.To develop a prediction model for the persistence of complaints, with distinction between patients with and without pre-existing morbidity (WP3);
5. 5.To develop a patient platform prototype in which patients can digitally consult their answers and compare their answers with reference populations (WP4, in collaboration with the EuroQol foundation).

Conditions

COVID-19; Long COVID; Post COVID-19 Condition

Keywords

Epidemiology; Pathophysiology; Prediction model; Patient platform

Outcome Measures

Primary Outcomes (1)

• Prevalence of long COVID complaints (based on data from all 7 cohorts)

  Long COVID complaints include: exhaustion, respiratory complaints, and mental health complaints.

  24 months follow-up after COVID-19

Secondary Outcomes (7)

• (Health-related) Quality of life (measured in all 7 cohorts)

  3, 6, 12, 18 and 24 months follow-up after COVID-19

• Anxiety and depression (measured in all 7 cohorts)

  3, 6, 12, 18 and 24 months follow-up after COVID-19

• Prevalence of thrombo-embolic complications (not measured in all 7 cohorts)

  Measured during COVID-19 hospitalization (baseline), 3, 12, 24 months follow-up after COVID-19

• Physical functioning (not measured in all 7 cohorts)

  Measured during admission in the rehabilitation clinic (baseline), 3, 6, 12 months follow-up

• Prevalence of cardiovascular diseases (not measured in all 7 cohorts)

  Measured during COVID-19 hospitalization (baseline), 1 week, 1 month, and through study completion, an average of 2 years

Study Arms (2)

Dutch COVID-19 patients

The study population consists of Dutch (former) COVID-19 patients who have been included in one of the cohorts and categorized in various subgroups: * Patients who suffered from (confirmed) COVID-19 and were admitted to the hospital ward. * Patient who suffered from (confirmed) COVID-19 and were admitted to the ICU. * Patients who suffered from (confirmed or suspected) COVID-19 at home. * Patients who suffered from (confirmed) COVID-19 and were in need of inpatient or outpatient rehabilitation after infection at home or in the hospital (ward and/or ICU).

Other: no intervention, the CORFU study conducts analyses based on data which has been prospectively collected (and aggregated when possible) in 7 existing cohorts

Dutch controls who did not experience COVID-19

One of the cohorts, the POPCOrn cohort, is a community-based cohort which partly consists of controls who did not experience COVID-19

Other: no intervention, the CORFU study conducts analyses based on data which has been prospectively collected (and aggregated when possible) in 7 existing cohorts

Interventions

no intervention, the CORFU study conducts analyses based on data which has been prospectively collected (and aggregated when possible) in 7 existing cohorts OTHER

(Clinical) baseline and follow-up data will be collected in the 7 existing cohorts. These data will be aggregated (when possible). The CORFU analyses will be conducted based on the aggregated data.

Also known as: Integrated database

Dutch COVID-19 patients; Dutch controls who did not experience COVID-19

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The study population consists of Dutch (former) COVID-19 patients and non-COVID-19 controls, who have been included in one of the cohorts and categorized in five subgroups: * Patients who suffered from (confirmed) COVID-19 and were admitted to the hospital ward. * Patient who suffered from (confirmed) COVID-19 and were admitted to the ICU. * Patients who suffered from (confirmed or suspected) COVID-19 at home. * Patients who suffered from (confirmed) COVID-19 and were in need of inpatient or outpatient rehabilitation after infection at home or in the hospital (ward and/or ICU). * Controls who did not suffer from (confirmed or suspected) COVID-19.

You may not qualify if:

• For the CORFU study, in general, the criteria are:
• Patients with proven or suspected COVID-19:
• Confirmed (or suspected) COVID-19 - both home-isolated patients and patients who were admitted to the hospital ward and/or ICU;
• Included in one of the seven cohorts from March 2020 onwards;
• Aged 18 years or older;
• Mastering the Dutch language sufficiently to answer the questionnaires;
• Informed consent.
• Controls who did not experience COVID-19:
• Aged 18 years or older;
• Mastering the Dutch language sufficiently to answer the questionnaires;
• Informed consent.

Sponsors & Collaborators

• Maastricht University Medical Center: lead
• Zuyderland Medical Centre: collaborator
• Leiden University Medical Center: collaborator
• UMC Utrecht: collaborator
• Radboud University Medical Center: collaborator
• Amsterdam University Medical Center: collaborator
• Adelante, Centre of Expertise in Rehabilitation and Audiology: collaborator

Study Sites (1)

Maastricht University Medical Center+

Maastricht, 6229HX, Netherlands

Location

Related Publications (12)

• Nicol B, Rowbotham DJ, Lambert DG. Glutamate uptake is not a major target site for anaesthetic agents. Br J Anaesth. 1995 Jul;75(1):61-5. doi: 10.1093/bja/75.1.61.

  PMID: 7669472 BACKGROUND

• Kozlov IA, Piliaeva IE, Matveev IuG, Kormer AIa. [Anesthesiological management in transplantation of the heart after temporary mechanical substitution of its function]. Anesteziol Reanimatol. 1994 Jan-Feb;(1):16-22. Russian.

  PMID: 8010503 BACKGROUND

• Keogh JP, Gordon J. Occupational lead poisoning: who should conduct surveillance and training? Am J Ind Med. 1994 Nov;26(5):713-5. doi: 10.1002/ajim.4700260513.

  PMID: 7832218 BACKGROUND

• Pittaluga A, Raiteri M. HIV-1 envelope protein gp120 potentiates NMDA-evoked noradrenaline release by a direct action at rat hippocampal and cortical noradrenergic nerve endings. Eur J Neurosci. 1994 Nov 1;6(11):1743-9. doi: 10.1111/j.1460-9568.1994.tb00566.x.

  PMID: 7874313 BACKGROUND

• Kaluzewski S, Jagielski M, Rastawicki W, Kochman M. [Evaluation of occurrence of infections caused by Mycoplasma pneumoniae during 1970-1973 based on serological investigations]. Przegl Epidemiol. 1994;48(3):165-72. Polish.

  PMID: 7938618 BACKGROUND

• Leijte WT, Wagemaker NMM, van Kraaij TDA, de Kruif MD, Mostard GJM, Leers MPG, Mostard RLM, Buijs J, van Twist DJL. [Mortality and re-admission after hospitalization with COVID-19]. Ned Tijdschr Geneeskd. 2020 Nov 19;164:D5423. Dutch.

  PMID: 33332036 BACKGROUND

• Haber J, Wattles J, Crowley M, Mandell R, Joshipura K, Kent RL. Evidence for cigarette smoking as a major risk factor for periodontitis. J Periodontol. 1993 Jan;64(1):16-23. doi: 10.1902/jop.1993.64.1.16.

  PMID: 8426285 BACKGROUND

• Skelton-Stroud PN, Glaister JR. Oxalate nephrosis in Macaca fascicularis. Lab Anim. 1994 Jul;28(3):265-9. doi: 10.1258/002367794780681705.

  PMID: 7526030 BACKGROUND

• Schwarz T, Sindern S, Bartholmes P, Kaufmann M. The use of a hollow fiber membrane module in sample conditioning prior to electrophoresis. Electrophoresis. 1994 Aug-Sep;15(8-9):1118-9. doi: 10.1002/elps.11501501168.

  PMID: 7859717 BACKGROUND

• Klein DO, Waardenburg SF, Janssen EBNJ, Wintjens MSJN, Imkamp M, Heemskerk SCM, Birnie E, Bonsel GJ, Warle MC, Jacobs LMC, Hemmen B, Verbunt J, van Bussel BCT, van Santen S, Kietelaer BLJH, Jansen G, Klok FA, de Kruif MD, Vernooy K, Haagsma JA, Asselbergs FW, Linschoten M, Cals JWL, Ten Cate H, van der Horst ICC, Wilmes N; CAPACITY-COVID Collaborative Consortium; Ghossein-Doha C, van Kuijk SMJ. Two years and counting: a prospective cohort study on the scope and severity of post-COVID symptoms across diverse patient groups in the Netherlands-insights from the CORFU study. BMJ Open. 2025 Sep 11;15(9):e093639. doi: 10.1136/bmjopen-2024-093639.

  PMID: 40940063 DERIVED

• Jacobs LMC, Wintjens MSJN, Nagy M, Willems L, Ten Cate H, Spronk HMH, van Kuijk SMJ, Ghossein-Doha C, Netea MG, Groh LA, van Petersen AS, Warle MC. Biomarkers of sustained systemic inflammation and microvascular dysfunction associated with post-COVID-19 condition symptoms at 24 months after SARS-CoV-2-infection. Front Immunol. 2023 Oct 5;14:1182182. doi: 10.3389/fimmu.2023.1182182. eCollection 2023.

  PMID: 37868959 DERIVED

• Ghossein-Doha C, Wintjens MSJN, Janssen EBNJ, Klein D, Heemskerk SCM, Asselbergs FW, Birnie E, Bonsel GJ, van Bussel BCT, Cals JWL, Ten Cate H, Haagsma J, Hemmen B, van der Horst ICC, Kietselaer BLJH, Klok FA, de Kruif MD, Linschoten M, van Santen S, Vernooy K, Willems LH, Westerborg R, Warle M, van Kuijk SMJ. Prevalence, pathophysiology, prediction and health-related quality of life of long COVID: study protocol of the longitudinal multiple cohort CORona Follow Up (CORFU) study. BMJ Open. 2022 Nov 29;12(11):e065142. doi: 10.1136/bmjopen-2022-065142.

  PMID: 36446465 DERIVED

Related Links

• CAPACITY COVID-19: Registry of patients with COVID-19 including cardiovascular risk and complications

MeSH Terms

Conditions

COVID-19; Post-Acute COVID-19 Syndrome

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Post-Infectious Disorders; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Sander MJ van Kuijk, PhD

  Maastricht University Medical Center

  PRINCIPAL INVESTIGATOR

• Chahinda Ghossein-Doha, MD, PhD

  Maastricht University Medical Center

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Epidemiologist

Study Record Dates

• First Submitted: November 26, 2021
• First Posted: February 15, 2022
• Study Start: October 1, 2021
• Primary Completion: January 1, 2024
• Study Completion: November 1, 2024
• Last Updated: October 1, 2025

Record last verified: 2024-11

Locations

NL (1)